ES2032922T3 - Empleo de los paf-aceter antagonicos para la fabricacion de un medicamento y procedimiento para determinar la eficacia de los mismos. - Google Patents

Empleo de los paf-aceter antagonicos para la fabricacion de un medicamento y procedimiento para determinar la eficacia de los mismos.

Info

Publication number
ES2032922T3
ES2032922T3 ES198888117022T ES88117022T ES2032922T3 ES 2032922 T3 ES2032922 T3 ES 2032922T3 ES 198888117022 T ES198888117022 T ES 198888117022T ES 88117022 T ES88117022 T ES 88117022T ES 2032922 T3 ES2032922 T3 ES 2032922T3
Authority
ES
Spain
Prior art keywords
paf
aceter
antagonic
effectiveness
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888117022T
Other languages
English (en)
Other versions
ES2032922T5 (es
Inventor
Ruth Dr. Med. Korth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6338731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2032922(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of ES2032922T3 publication Critical patent/ES2032922T3/es
Application granted granted Critical
Publication of ES2032922T5 publication Critical patent/ES2032922T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LAS SUSTANCIAS QUE INHIBEN LOS LUGARES DE ENLACE DE PAF - ACETER EN LAS CELULAS SE APLICAN PARA EL TRATAMIENTO DE ENFERMEDADES ORIGINADAS POR UNA BAJADA DE LA BARRERA DE CELULAS DEL ENDOTELIO.
ES88117022T 1987-10-20 1988-10-13 Empleo de los antagonicos de parf-aceter para la fabricacion de un medicamento para la prevencion de arteriosclerosis. Expired - Lifetime ES2032922T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3735525A DE3735525C2 (de) 1987-10-20 1987-10-20 Verfahren zur Bestimmung der Wirksamkeit von paf-Acether-Rezeptor-Antagonisten

Publications (2)

Publication Number Publication Date
ES2032922T3 true ES2032922T3 (es) 1993-03-01
ES2032922T5 ES2032922T5 (es) 1996-05-01

Family

ID=6338731

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88117022T Expired - Lifetime ES2032922T5 (es) 1987-10-20 1988-10-13 Empleo de los antagonicos de parf-aceter para la fabricacion de un medicamento para la prevencion de arteriosclerosis.

Country Status (7)

Country Link
EP (1) EP0312913B2 (es)
JP (1) JP2539257B2 (es)
AT (1) ATE72113T1 (es)
AU (1) AU613672B2 (es)
DE (1) DE3735525C2 (es)
ES (1) ES2032922T5 (es)
GR (2) GR3004464T3 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30676A (en) * 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
US5895785A (en) * 1987-10-20 1999-04-20 Ruth Korth Treatment and prevention of disorders mediated by LA-paf or endothelial cells
DE4244265C2 (de) * 1992-12-28 1999-08-12 Korth Ruth Maria Verwendung von Paf-Antagonisten gegen die neue Ausbildung von Paf-Bindungsstellen auf endothelialen Zellen zur Behandlung oder Vorbeugung des Hyperinsulinismus
DE4017818C2 (de) * 1990-06-06 2001-02-15 Korth Ruth Maria Verfahren zur Überprüfung von Substanzen auf ihre Wirksamkeit als paf-Acether-Antagonisten
US5530023A (en) * 1987-10-20 1996-06-25 Korth; Ruth Production of binding sites for PAF, PAF analogues and PAF antagonists in endothelial cells
GB8725871D0 (en) * 1987-11-04 1987-12-09 Scras Ginkgolide derivatives
DE69132379T2 (de) * 1990-06-06 2001-03-01 Ruth-Maria Korth Behandlung von Erkrankungen mit Paf-Antagonisten und Verfahren zur Bestimmung deren Wirksamkeit
ES2181665T3 (es) * 1991-11-04 2003-03-01 Ruth-Maria Korth Tratamiento y prevencion de enfermedades mentales, acompañadas por unos elevados niveles de liso paf, con los antagonistas de paf.
DE540766T1 (de) 1991-11-04 2002-11-28 Ruth-Maria Korth Behandlung von Eosinophil-mediierten Erkrankungen mit PAF-Antagonisten, und Verfahren zur Bestimmung deren Effektivität.
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
DE102005062417A1 (de) * 2005-12-27 2007-08-23 Korth, Ruth-Maria, Dr.med. Kompositionen mit spezifischen und unspezifischen Lipidantagonisten
US11039997B2 (en) 2005-12-27 2021-06-22 Ruth-Maria Korth Cosmetic, dermatic, protective compositions comprising phospholipids, lecithins with peptides and at least one acetylating compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8418424D0 (en) * 1984-07-19 1984-08-22 Scras Inhibition of platelets aggregation
DE3710921C2 (de) * 1986-10-21 1996-09-26 Korth Ruth Verwendung der Gingkolide BN 52020, BN 52021 und BN 52063 zur Behandlung von Arteriosklerose
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
DE3816169A1 (de) * 1988-05-11 1989-11-23 Boehringer Ingelheim Kg Verwendung und mittel zur verminderung der nebenwirkungen von tnf

Also Published As

Publication number Publication date
AU613672B2 (en) 1991-08-08
AU2394388A (en) 1989-04-20
JP2539257B2 (ja) 1996-10-02
DE3735525C2 (de) 1997-02-20
GR3018869T3 (en) 1996-05-31
GR3004464T3 (en) 1993-03-31
DE3735525A1 (de) 1989-05-03
EP0312913B2 (de) 1995-12-20
EP0312913A2 (de) 1989-04-26
EP0312913B1 (de) 1992-01-29
JPH0291020A (ja) 1990-03-30
EP0312913A3 (en) 1990-01-31
ES2032922T5 (es) 1996-05-01
ATE72113T1 (de) 1992-02-15

Similar Documents

Publication Publication Date Title
DE3381675D1 (de) Einverleibung von polymeren in biologischen implantierbaren geweben zum hemmen von verkalkung.
DE3789320D1 (de) Verabreichungsinstrument zum Einführen von festen Medikamenten.
EG19912A (en) The use of the active substance azelastine in combatting psoriasis disorders and inflammatory disorders
ES2032922T3 (es) Empleo de los paf-aceter antagonicos para la fabricacion de un medicamento y procedimiento para determinar la eficacia de los mismos.
BR8906471A (pt) Conjuntos de esteira para trator
IT1224886B (it) Monoesteri idrosolubili impiegabili come solubilizzanti per sostanze farmacologicamente attive
DK435688A (da) Farmaceutiske midler
IT8149623A0 (it) Derivati encefalinici dotati di attivita' analgesica e composizioni farmaceutiche che li contengono
DE3781483D1 (de) Pharmazeutische zusammensetzung zum schutz von gehirnzellen.
FR2566662B1 (fr) Association medicamenteuse utilisee en photochimiotherapie
MA19907A1 (fr) Procede de preparation de derives de la thiatriazine et utilisation de ceux-ci dans des compositions pharmaceutiques.
FR2580497B1 (fr) Compositions pharmaceutiques en comprimes
ATA133288A (de) Pharmazeutische zusammensetzung
IT8720800A0 (it) Composto attivo nella terapia carciovascolare.
FR2618676B1 (fr) Compositions pharmaceutiques antivirales
ES1000381Y (es) Calzado biolectromagnetico para uso terapeutico y general
ES2165366T3 (es) Procedimientos y composiciones para inhibir la inflamacion mediada por celulas endoteliales y fibrinogeno.
BR1100204A (pt) Composição farmacêutica para tratar esquizofrenia
KR890001887U (ko) 산림의 유해식물 제거용 약물주사기
ATE10098T1 (de) Beta-carbolin-3-carbonsaeure-derivate, sie enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung.
IT8448370A0 (it) Citrato trisodico utilizzabile nella cura delle malattie artriticoreumatiche
IT8323927A0 (it) Derivati benzilidenici alchilati loro preparazione e loro impiego in terapia.
IT1129876B (it) Medicamento utilizzabile in oftalmo logia
IT8024962A0 (it) Derivati dell'ossayohimbano e loro impiego in terapeutica.
ES1010158Y (es) Dispositivo para la manipulacion de perfiles en instalaciones para tratamiento de los mismos.